Clinical trial readout dates for Scholar Rock Holding Corporation, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.
| Phase 2 Apitegromab Spinal muscular atrophy (SMA) | date not published Trial Planned |
| Phase 2 SRK-439 with apitegromab Obesity | date not published Ongoing |
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 2 Apitegromab (SRK-015) Spinal muscular atrophy (SMA) | January 19, 2021 Ongoing |
Scholar Rock Holding Corporation reported $414M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-10). Its net loss for that quarter was $107M; at that rate the cash would last about 4 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Reg FD Disclosure — often a data announcement | 2026-11-10 |